ProPetro Q3 2026 swings to $13 million net profit from prior-quarter loss
Bitget2026/10/28 11:02- ProPetro swung to third-quarter 2026 net income of $13 million from a loss in the second quarter.
- Revenue rose 16% from the second quarter to $355 million, driven by higher completions utilization and incremental PROPWR deployments.
- Operating cash flow fell 30% from the second quarter to $46.31 million due primarily to working capital headwinds.
- PROPWR’s contracted capacity reached approximately 510 megawatts, including approximately 230 megawatts under its Targa agreement.
- Deployment targets call for approximately 250–275 megawatts by year-end 2026 and more than 500 megawatts by early 2028.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Rocket Lab’s stock falls as quarterly loss exceeds expectations
BUZZ-Take-Two shares rise after raising annual revenue and profit forecasts
Itaúsa Q3 2026 recurring net profit rises 25% to R$ 5.06 billion year-on-year
The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.
NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.
Crypto prices
More
